MoonLake (MLTX) — A Regulated Path to Upside Without Clinical Supremacy
MoonLake Immunotherapeutics has a binary pipeline headline in sonelokimab, but the bull case doesn't require clinical dominance — only regulatory acceptance and a commercially viable label. With recent FDA nods, solid Week 40 Phase 3 signals in hidradenitis suppurativa (HS), a $200M offering that thickens the cash runway, and elevated short interes…